BioSpace News Archive

Company will have two presentations at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting on November 6-10, 2019 at the Gaylord National Convention Center in National Harbor, MD.

Progenics Has Again Resorted to False Information and Misleading Innuendo in Seemingly Desperate Attempt to Avoid Accountability and Deprive Stockholders of Chance to Realize Company’s Full Value

Radius Health announced that it will release its third quarter 2019 financial results on Tuesday, November 5, 2019.

SALT LAKE CITY, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that the U.S. Food and Drug Administration (FDA) approved myChoice ® CDx for use as a companion diagnostic by healthcare professionals to identify women with advanced ovarian cancer who are candidates for Zejula ® (niraparib) in the late-line treatment setting. GlaxoSmithKline also announced that it received approval from the FDA for

New data show ReNeuron’s lead CTX cell therapy candidate can be re-programmed into a pluripotent state and differentiated into other cell types

EXMceuticals Inc. announces that it has applied for a voluntary management cease trade order in accordance with National Policy 12-203 due to it not being able to file its annual financial statements and MD&A for the year ended June 30, 2019 on SEDAR within 120 days of its financial year-end..

PTC Therapeutics, Inc. announced that on October 18, 2019 it approved non-statutory stock options to purchase an aggregate of 144,150 shares of its common stock to 29 new employees.

The Public Health Agency of Canada is collaborating with provincial public health partners, the Canadian Food Inspection Agency and Health Canada to investigate an outbreak of Salmonella infections occurring in Ontario and Quebec.

OpGen, Inc. announced the pricing of an underwritten offering of an aggregate of 4,700,000 units at an effective price of $2.00 per unit.

Eli Lilly and Company announced that Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of service with the company.